Samuel M. Moskowitz

12.2k total citations · 2 hit papers
70 papers, 5.6k citations indexed

About

Samuel M. Moskowitz is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Molecular Medicine. According to data from OpenAlex, Samuel M. Moskowitz has authored 70 papers receiving a total of 5.6k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 30 papers in Molecular Biology and 21 papers in Molecular Medicine. Recurrent topics in Samuel M. Moskowitz's work include Cystic Fibrosis Research Advances (35 papers), Bacterial biofilms and quorum sensing (23 papers) and Antibiotic Resistance in Bacteria (21 papers). Samuel M. Moskowitz is often cited by papers focused on Cystic Fibrosis Research Advances (35 papers), Bacterial biofilms and quorum sensing (23 papers) and Antibiotic Resistance in Bacteria (21 papers). Samuel M. Moskowitz collaborates with scholars based in United States, Australia and Canada. Samuel M. Moskowitz's co-authors include Samuel I. Miller, Jane L. Burns, Robert K. Ernst, Bonnie W. Ramsey, David P. Speert, Julia Emerson, Eric E. Smith, Rajinder Kaul, Maynard V. Olson and Zaining Wu and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Samuel M. Moskowitz

68 papers receiving 5.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients

2006 1.0k citations Eric E. Smith, Danielle Buckley et al. Proceedings of the National Academy of Sciences profile →
VX-445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles

2018 500 citations Gautham Marigowda, Marcus Mall et al. profile →

Peers

Countries citing papers authored by Samuel M. Moskowitz

Since Specialization

Citations

This map shows the geographic impact of Samuel M. Moskowitz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel M. Moskowitz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel M. Moskowitz more than expected).

Fields of papers citing papers by Samuel M. Moskowitz

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel M. Moskowitz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel M. Moskowitz. The network helps show where Samuel M. Moskowitz may publish in the future.

Co-authorship network of co-authors of Samuel M. Moskowitz

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel M. Moskowitz. A scholar is included among the top collaborators of Samuel M. Moskowitz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel M. Moskowitz. Samuel M. Moskowitz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Physiologically Based Pharmacokinetic Modeling of CFTR Modulation in People with Cystic Fibrosis Transitioning from Mono or Dual Regimens to Triple-Combination Elexacaftor/Tezacaftor/Ivacaftor 2020 ·Pulmonary Therapy ·Alice Tsai, (unknown), Eric L. Haseltine, Sanjeev Kumar, Samuel M. Moskowitz, (unknown), Kushal Shah	26
2	PRS77 Application of the Cfq-R-8D to Estimate Utility Benefit of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in People with Cystic Fibrosis (CF) 2020 ·Value in Health ·Lisa J. McGarry, (unknown), (unknown), Jason X.‐J. Yuan, (unknown), Yiyue Lou, Samuel M. Moskowitz	2
3	Phase 3 efficacy and safety of the ELX/TEZ/IVA triple combination in people with CF homozygous for the F508DEL mutation 2019 ·Ghent University Academic Bibliography (Ghent University) ·Harry Heijerman, (unknown), D.G. Downey, Marcus Mall, Bonnie W. Ramsey, Steven M. Rowe, (unknown), Eva Van Braeckel, John Welter, Neil Ahluwalia, Gautham Marigowda, (unknown), Samuel M. Moskowitz, (unknown), Patrick R. Sosnay, David S. Goldfarb, Fengjuan Xuan, (unknown), Jennifer L. Taylor‐Cousar, Karen McCoy	2
4	Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or twoF508delalleles 2019 ·ERJ Open Research ·Jennifer L. Taylor‐Cousar, Marcus Mall, Bonnie W. Ramsey, Edward F. McKone, Elizabeth Tullis, Gautham Marigowda, Charlotte McKee, David Waltz, Samuel M. Moskowitz, J. R. K. Savage, Fengjuan Xuan, Steven M. Rowe	79
5	Carbon Sources Tune Antibiotic Susceptibility in Pseudomonas aeruginosa via Tricarboxylic Acid Cycle Control 2017 ·Cell chemical biology ·Sylvain Meylan, Caroline Porter, Jason H. Yang, Peter Belenky, Arnaud Gutierrez, Michael A. Lobritz, Jihye Park, Sun H. Kim, Samuel M. Moskowitz, James J. Collins	282
6	The CF-CARES primary palliative care model: A CF-specific structured assessment of symptoms, distress, and coping 2017 ·Journal of Cystic Fibrosis ·Deborah Friedman, Rachel W. Linnemann, Lily L. Altstein, (unknown), (unknown), (unknown), John D. Volpe, (unknown), (unknown), Patricia J. O’Malley, Gregory S. Sawicki, Anna M. Georgiopoulos, Lael M. Yonker, Samuel M. Moskowitz	19
7	Development and evaluation of a palliative care curriculum for cystic fibrosis healthcare providers 2015 ·Journal of Cystic Fibrosis ·Rachel W. Linnemann, Patricia J. O’Malley, Deborah Friedman, Anna M. Georgiopoulos, David Buxton, Lily L. Altstein, Leonard Sicilian, Allen Lapey, Gregory S. Sawicki, Samuel M. Moskowitz	28
8	Rhesus θ-defensin-1 (RTD-1) exhibitsin vitroandin vivoactivity against cystic fibrosis strains ofPseudomonas aeruginosa 2015 ·Journal of Antimicrobial Chemotherapy ·Paul M. Beringer, (unknown), Henry C. Ho, Melissa Agnello, (unknown), (unknown), Annie Wong‐Beringer, Rosemary C. She, Dat Q. Tran, Samuel M. Moskowitz, Michael E. Selsted	22
9	Azithromycin May Antagonize Inhaled Tobramycin When Targeting Pseudomonas aeruginosa in Cystic Fibrosis 2014 ·Annals of the American Thoracic Society ·Jerry A. Nick, Samuel M. Moskowitz, James F. Chmiel, Anna Forssén, Sun Ho Kim, Milene T. Saavedra, Lisa Saiman, Jennifer L. Taylor‐Cousar, David P. Nichols	50
10	Pyocyanin-Enhanced Neutrophil Extracellular Trap Formation Requires the NADPH Oxidase 2013 ·PLoS ONE ·Balázs Rada, (unknown), Lan Pang, (unknown), (unknown), Jonathan J. Park, Samuel M. Moskowitz, Harry L. Malech, Thomas L. Leto	104
11	Randomized trial of biofilm testing to select antibiotics for cystic fibrosis airway infection 2010 ·Pediatric Pulmonology ·Samuel M. Moskowitz, Julia Emerson, Sharon McNamara, (unknown), David M. Orenstein, Daniel Rosenbluth, Marcia Katz, Richard C. Ahrens, Douglas B. Hornick, Patricia M. Joseph, Ronald L. Gibson, Moira L. Aitken, Wade W. Benton, Jane L. Burns	59
12	Colistin susceptibility testing: evaluation of reliability for cystic fibrosis isolates of Pseudomonas aeruginosa and Stenotrophomonas maltophilia 2010 ·Journal of Antimicrobial Chemotherapy ·Samuel M. Moskowitz, Elizabeth Garber, Yunhua Chen, Sarah A. Clock, Setareh Tabibi, Amanda Miller, (unknown), Lisa Saiman	54
13	Mechanisms of bacterial virulence in pulmonary infections 2009 ·Current Opinion in Critical Care ·Samuel M. Moskowitz, Jeanine P. Wiener-Kronish	11
14	Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients 2008 ·Journal of Cystic Fibrosis ·Helle Krogh Johansen, Samuel M. Moskowitz, Oana Ciofu, Tacjana Pressler, Niels Høiby	123
15	Clinical practice and genetic counseling for cystic fibrosis and CFTR-related disorders 2008 ·Genetics in Medicine ·Samuel M. Moskowitz, James F. Chmiel, (unknown), Kwang‐Ting Cheng, Ronald L. Gibson, Susan G. Marshall, Garry R. Cutting	105
16	Unique Lipid A Modifications inPseudomonas aeruginosaIsolated from the Airways of Patients with Cystic Fibrosis 2007 ·The Journal of Infectious Diseases ·Robert K. Ernst, Samuel M. Moskowitz, Julia Emerson, (unknown), Kristin N. Adams, (unknown), Bonnie W. Ramsey, David P. Speert, Jane L. Burns, Samuel I. Miller	91
17	Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients breakdown → 2006 ·Proceedings of the National Academy of Sciences ·Eric E. Smith, Danielle Buckley, Zaining Wu, Channakhone Saenphimmachak, Lucas R. Hoffman, David A. D’Argenio, Samuel I. Miller, Bonnie W. Ramsey, David P. Speert, Samuel M. Moskowitz, Jane L. Burns, Rajinder Kaul, Maynard V. Olson	1047
18	Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection 2005 ·Journal of Antimicrobial Chemotherapy ·Samuel M. Moskowitz, (unknown), Julia Emerson, Ronald L. Gibson, Jane L. Burns	37
19	Cystic fibrosis lung disease: genetic influences, microbial interactions, and radiological assessment 2005 ·Pediatric Radiology ·Samuel M. Moskowitz, Ronald L. Gibson, Eric L. Effmann	27
20	Pandoraea Bacteremia in a Cystic Fibrosis Patient With Associated Systemic Illness 2004 ·The Pediatric Infectious Disease Journal ·(unknown), Jin-Young Han, Samuel M. Moskowitz, Jane L. Burns, Xuan Qin, Janet A. Englund	35

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact